Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. - Wikidata - awgldk - TriplyDB

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.

http://www.wikidata.org/entity/Q40386808

about

Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.Fatal graft-versus-host disease after allogeneic stem cell transplantation in a patient recently exposed to nivolumab.Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.Hodgkin lymphoma: A review and update on recent progress.Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors.Advances in immunotherapy for pediatric acute myeloid leukemia.Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma.Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.Transplant strategies in relapsed/refractory Hodgkin lymphoma.Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma.Fertility preservation in Hodgkin's lymphoma patients that undergo targeted molecular therapies: an important step forward from the chemotherapy era.Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide

P2860

Q33704061-213B28F3-25D9-4A81-ACA9-5799C1831DD8 Q33886267-517701EA-4EFA-4B87-96B5-7F2B08E2CECF Q38700459-D97856BA-2C6E-4007-9AC1-0B38C334F6B9 Q39259769-A935CA5F-B290-4948-A67A-3DF8B562214F Q39294879-C4471BB2-A5F5-445A-84C8-44DFAFBA569F Q39307476-8DD4AB2A-C902-4672-89DF-AF7180C73262 Q40216708-4167A8EB-B6AE-492C-B541-E355117018D8 Q47364293-39E2D381-04D4-473B-94E9-7FBFA20EB4EA Q47394131-FD49CA3D-C61E-43AA-A187-CFE7FDFF0ADC Q47807176-37F2AD25-537D-445B-81D2-0A18B6C28C2A Q47855599-7A538313-39A6-44A3-9B03-E36A05E90CF3 Q47930962-033A3F35-5980-4FB2-ABE8-4AC9843E64E6 Q47952363-11C19CF9-9107-4709-B646-C43C94D4C289 Q48689919-61E5C739-94AE-4A70-851E-EA541AE76422 Q50271165-DC6C8DB9-6E04-4149-9B1D-8ADCD54E2C0E Q52676516-F53D5ED8-64AE-4938-B4D4-52887A4D8D0E Q52721221-7DACF716-C455-446D-8AC8-F2B29590E40C Q52777496-33B0293A-84F7-476E-BD3C-06F171822B39 Q55341751-2327EAA7-FE5B-47F6-8128-7F8AEA48D518 Q56383260-2D828A2C-E195-47A1-A959-2E090F6585E9 Q58761583-3D07B779-80DB-45AD-962A-367A4D3EDBD2

P2860

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.

http://www.wikidata.org/entity/Q40386808

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Safety and efficacy of allogen ...... relapsed/refractory lymphoma.

@en

type

label

Safety and efficacy of allogen ...... relapsed/refractory lymphoma.

@en

prefLabel

Safety and efficacy of allogen ...... relapsed/refractory lymphoma.

@en

P1433

Q40386808-2D12FA79-4446-4D46-B106-335533B67979

P1476

Q40386808-5520DE45-21FA-43BF-B698-F2D2B48A52B2

P2093

Q40386808-122FA036-4139-4B92-904E-356622143D16

Q40386808-142B944C-F12B-4AF9-8626-BE9B276793DB

Q40386808-19A0C096-6CD8-4D33-BF11-A46880EB9226

Q40386808-1E28F1B8-88E2-4162-8E6C-EA6B229BB618

Q40386808-1F60BC9F-FC9B-4075-9445-4AF176EA4375

Q40386808-2C4F1E61-7C55-4F6B-8482-1E33C854D5AD

Q40386808-2E63864E-6C90-456C-8CAA-80CDFA6085E5

Q40386808-416A430C-99F6-480A-B932-7BE38C3E57BD

Q40386808-5B174C5A-1DA7-4820-89F7-EF93303391B4

Q40386808-7DD91880-3D15-4576-BC88-4DD265F9D0F6

P2860

Q40386808-05D23E1F-5249-40ED-A490-3BB64C3171F6

Q40386808-0ED4E489-1192-4DC1-B5DC-052532BF6720

Q40386808-0EDFA77E-3FAC-42FE-B596-84872FC4BE7C

Q40386808-108FDCED-A822-4CCB-B836-ABDDBCC3BCF6

Q40386808-14418C3E-F34F-4BD8-8D75-8984A1FABDFB

Q40386808-1FEACC7E-3AC2-4DFA-8990-722DE19CD918

Q40386808-213067CA-6C15-4E4F-8380-8D831FE110E7

Q40386808-22BDEAAD-9CAC-4F35-91A5-DCE38496A4D0

Q40386808-3B08E19C-0004-4A57-9A76-6CEE2DA76656

Q40386808-4196114C-5738-47C8-992B-4BD6672C5874

P304

Q40386808-97364B36-0CA2-45A3-92F3-D2C3EFF0BF59

P31

Q40386808-9BE68456-F1BA-4E80-9AEB-07E1056A15D0

P356

Q40386808-C31D397D-3274-4F8A-9DD5-60C4F57C57A8

P407

Q40386808-221CA368-CEEC-4D62-8728-8A1C2CBE86C7

P433

Q40386808-EABF2E43-2A20-4887-8E3B-0E94F861AAB3

P478

Q40386808-A20DB61A-9AC0-4E1A-AD8B-5362C39FF2B9

P50

Q40386808-81D6128D-F2A2-4DB1-B3D7-5F492CECCFA1

Q40386808-A3F8437A-EBCF-4CDD-A1B8-FDED3D5E124D

Q40386808-B148A85A-D8BB-4170-8FF5-7DC803BF0F06

Q40386808-B77B3D78-2821-4AAA-BDAC-5F1F0D16B316

P577

Q40386808-5DCEE663-8B54-4D7E-BC6F-AC2CAF565612

P698

Q40386808-27B6A7EF-96A8-405A-9A98-49AC8A2892AF

P932

Q40386808-4AEA4C52-8045-4E79-8C3A-9FE0E3527599

P356

BLOOD-2016-09-738385

P1433

P1476

Safety and efficacy of allogen ...... n relapsed/refractory lymphoma

@en

P2093

Abraham Avigdor

http://www.w3.org/2001/XMLSchema#string

Ahmad S Halwani

http://www.w3.org/2001/XMLSchema#string

Amitabh Srivastava

http://www.w3.org/2001/XMLSchema#string

Armando Santoro

http://www.w3.org/2001/XMLSchema#string

Aspasia Stamatoullas-Bastard

http://www.w3.org/2001/XMLSchema#string

Carol Reynolds

http://www.w3.org/2001/XMLSchema#string

Emily Pesek

http://www.w3.org/2001/XMLSchema#string

Haesook T Kim

http://www.w3.org/2001/XMLSchema#string

Harim Kim

http://www.w3.org/2001/XMLSchema#string

Hélène Labussière Wallet

http://www.w3.org/2001/XMLSchema#string

P2860

Improved endpoints for cancer immunotherapy trials

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade.

Engraftment syndrome following hematopoietic stem cell transplantation.

Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes

The PDL1-PD1 axis converts human TH1 cells into regulatory T cells.

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

P304

1380-1388

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2016-09-738385

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

129

http://www.w3.org/2001/XMLSchema#string

P50

Carmelo Carlo-Stella

Veronika Bachanova

Pier Luigi Zinzani

Anne Thiébaut-Bertrand

P577

2017-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28073785

http://www.w3.org/2001/XMLSchema#string

P932

5345733

http://www.w3.org/2001/XMLSchema#string